Sequestration Saps 40% of Framingham Heart Study’s Budget

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The famed Framingham Heart Study, the longest-running cardiovascular disease clinical trial in the U.S., faces layoffs and closures as its annual budget drops from $9 million to $4 million amid federal sequestration. The famed Framingham Heart Study lost 40% of its budget to sequestration, which means layoffs and closures are on the way for the nation’s longest-running cardiovascular disease trial. The study lost $4 million of its annual $9 million budget thanks to automatic funding cuts that took effect amid federal sequestration, TheHeart.org reported.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC